London, Ontario (February 14, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today that Dr. Wayne Danter, President and CEO, will be delivering a podium presentation on February 19, 2012 at 10:15am PT at the Emerging Targeted Oncology Partnering Forum being held at the InterContinental Hotel in San Francisco, CA. The presentation is entitled COTI-2: A Highly Effective and Selective Allosteric Modulator/Inhibitor of AKT/AKT2.
The presentation will highlight the scientific results from recent pharmacodynamic and pharmacokinetic experiments, which demonstrate COTI-2’s ability to inhibit significantly the growth of cancer cells that over express AKT/AKT2, confirming it as a targeted therapy candidate. “This upcoming presentation affords us the opportunity to highlight the potential of COTI-2 to a scientific audience of key influencers from many partnering organizations,” said Dr. Danter. “COTI-2’s development is progressing very well. We recently announced the identification of oral formulation candidates and we are sharing that information with prospective partners under non-disclosure agreements. We look forward to presenting that data at similar scientific venues in the near future.” COTI is currently evaluating potential partners with an interest in moving this novel, targeted anti-cancer drug candidate through development and to the market in indications where significant unmet medical need exists.
During preclinical testing, COTI-2 has demonstrated greater selectivity, an improved safety profile and superior pharmacokinetics in comparison to other AKT targeted compounds. Over expression of AKT/AKT2 is common in a broad range of human cancers, including ovarian, endometrial, pancreatic, breast, colorectal and lung. The percent of tumors with active AKT/AKT2 range from 20% to 100% depending on the cancer type. COTI-2 is the most advanced compound in COTI’s pipeline discovered through CHEMSAS®, its proprietary artificial intelligence platform.
About Critical Outcome Technologies Inc. (COTI)
COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI’S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with high probability of being successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com or contact:
Michael Barr
Vice President of Business Development and Marketing
519-858-5157
mbarr@criticaloutcome.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
